Skip to main content

Advertisement

Table 2 Comparing patients under diagnostic-driven therapy with voriconazole and those under empiric antifungal therapy with voriconazole Characteristics

From: Treating invasive aspergillosis in patients with hematologic malignancy: diagnostic-driven approach versus empiric therapies

Characteristics and outcomes Diagnostic-driven therapy with voriconazole Empiric antifungal therapy with voriconazole p - value
(n = 44) (n = 77)
N (%) N (%)
Age (years), median (range) 63 (23–81) 58 (22–86) 0.10
Gender, male 26 (59) 46 (60) 0.94
Diagnosis of IA    0.06
 Definite IA 4/43 (9) 18 (23)  
 Probable IA 39/43 (91) 59 (77)  
Invasive pulmonary infection a 40 (91) 68 (88) 0.77
Disseminated infectiona 2 (5) 6 (8) 0.71
Localized or sinus infectiona 4 (9) 3 (4) 0.25
Leukemia 19 (43) 55 (71) 0.002
Lymphoma 16 (36) 16 (21) 0.06
Myeloma 8 (18) 4 (5) 0.029
Transplantation within 1 year prior to infection 16 (36) 34 (44) 0.40
Type of transplantation within prior year    0.14
 Allogeneic transplant 10/16 (63) 29/34 (85)  
 Autologous transplant 6/16 (38) 5/34 (15)  
Graft vs Host Disease (GVHD) 8/10 (80) 22/29 (76) > .99
Neutropenia (< 500 ANC) at onset of IA 8/42 (19) 29/73 (40) 0.022
Persistent neutropenia 14/36 (39) 21/64 (33) 0.54
Received immunotherapy 10/43 (23) 37/76 (49) 0.006
Received WBC transfusion 2/42 (5) 8 (10) 0.49
Year of IA diagnosis/treatment    0.73
 1993–2004 8 (18) 16 (21)  
 2005–2016 36 (82) 61 (79)  
Prophylactic antifungal treatment prior to 7 (16) 27/76 (36) 0.022
infection    
Breakthrough 6/7 (86) 25/26 (96) 0.38
Response to therapy 32 (73) 39 (51) 0.018
Death within 42 days of starting therapy 2 (5) 7/76 (9) 0.48
Aspergillosis-attributable death within 42 days of starting therapy 2 (5) 6/76 (8) 0.71
  1. aOne patient had all 3 types of IA infections